ClinicalTrials.gg

Program

codrituzumab

Also written as “GC33” and “GC33(RO5137382)”.

Its studies are mostly in Carcinoma, Hepatocellular, led by Hoffmann-La Roche.

Furthest: phase 2, since Jan 6, 20123 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche30 open or runningphase 2since Jan 6, 2012Sep 1, 2008none ahead
  • Named in Hoffmann-La Roche’s own pipeline as CHU codrituzumab, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2008First study: phase 1 study in Advanced or Metastatic HCCFirst studyNCT00746317 · 27 enrolled · United States
  2. Sep 9, 2009Phase 1 study in Carcinoma, HepatocellularNCT00976170 · 42 enrolled · United States, Taiwan
  3. Jan 6, 2012Phase 2 study in Carcinoma, HepatocellularNCT01507168 · 185 enrolled · United States, Belgium, France and more

TargetBeta

“A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell de…”NCIt, read by Claude

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
GPC3-targeted Plasmid DNA Vaccine NWRD06ruleNewish Biotech (Wuxi)phase 22
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 11
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 11
ACE723ruleacepodia-biotech-incphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01507168Carcinoma, Hepatocellular · United States, Belgium, France and more2CompletedAug 20, 2015185
NCT00976170Carcinoma, Hepatocellular · United States, Taiwan1CompletedJul 201342
NCT00746317Advanced or Metastatic HCC · United States1CompletedOct 201027

How it is read

Names in the registry

  • “GC33”, 2 entries
  • “GC33(RO5137382)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.